BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 33482770)

  • 21. Patients with initial nodal involvement due to breast cancer who have received neoadjuvant chemotherapy: Combined sentinel node-radioguided surgery of the pathological node.
    Fuertes Manuel J; Kohan S; Jordà Solé M; Mateu Hidalgo I; Miralles Curto M; Aguiló Sagristà O; Aguilar Alomá E; Peña González K; Lafuerza Torres A; Melé Olivé M; Repkova J; Montero Jaime MJ; Gumà Padró J
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2022; 41(5):284-291. PubMed ID: 35597764
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Surgical Management of the Axilla in Patients with Occult Breast Cancer (cT0 N+) After Neoadjuvant Chemotherapy.
    Cohen BL; Collier AL; Kelly KN; Goel N; Kesmodel SB; Yakoub D; Moller M; Avisar E; Franceschi D; Macedo FI
    Ann Surg Oncol; 2020 Jun; 27(6):1830-1841. PubMed ID: 31989360
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The use of ultrasound in the clinical re-staging of the axilla after neoadjuvant chemotherapy (NACT).
    Peppe A; Wilson R; Pope R; Downey K; Rusby J
    Breast; 2017 Oct; 35():104-108. PubMed ID: 28704697
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The feasibility and the role of sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer].
    Péley G; Török K; Farkas E; Mátrai Z; Horváth Z; Sinkovics I; Hitre E; Rényi-Vámos F; Orosz Z; Köves I
    Magy Onkol; 2006; 50(1):19-23. PubMed ID: 16617379
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcome following sentinel lymph node biopsy-guided decisions in breast cancer patients with conversion from positive to negative axillary lymph nodes after neoadjuvant chemotherapy.
    Kang YJ; Han W; Park S; You JY; Yi HW; Park S; Nam S; Kim JH; Yun KW; Kim HJ; Ahn SH; Park S; Lee JE; Lee ES; Noh DY; Lee JW
    Breast Cancer Res Treat; 2017 Nov; 166(2):473-480. PubMed ID: 28766131
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Normalization in axillary lymph node management after neoadjuvant therapy for breast cancer].
    Wu D; Liu SY; Amina M; Fan ZM
    Zhonghua Wai Ke Za Zhi; 2019 Feb; 57(2):97-101. PubMed ID: 30704211
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systemic Therapy Advances for HER2-Positive and Triple Negative Breast Cancer: What the Surgeon Needs to Know.
    Downs-Canner S; Weiss A
    Clin Breast Cancer; 2024 Jun; 24(4):328-336. PubMed ID: 38616443
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Surgical Management of the Axilla in Clinically Node-Positive Patients Receiving Neoadjuvant Chemotherapy: A National Cancer Database Analysis.
    Wong SM; Weiss A; Mittendorf EA; King TA; Golshan M
    Ann Surg Oncol; 2019 Oct; 26(11):3517-3525. PubMed ID: 31342389
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Axillary Surgery Following Neoadjuvant Chemotherapy - Multidisciplinary Guidance From the Association of Breast Surgery, Faculty of Clinical Oncology of the Royal College of Radiologists, UK Breast Cancer Group, National Coordinating Committee for Breast Pathology and British Society of Breast Radiology.
    Gandhi A; Coles C; Makris A; Provenzano E; Goyal A; Maxwell AJ; Doughty J
    Clin Oncol (R Coll Radiol); 2019 Sep; 31(9):664-668. PubMed ID: 31229382
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management of the axilla following neoadjuvant chemotherapy for breast cancer- A change in practice.
    Riogi B; Sripadam R; Barker D; Harris O; Innes H; Chagla L
    Surgeon; 2021 Feb; 19(1):1-7. PubMed ID: 32192932
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Management of the axilla in postmenopausal patients with cN0 hormone receptor-positive/HER2-negative breast cancer treated with neoadjuvant endocrine therapy and its prognostic impact.
    Garcia-Tejedor A; Falo C; Fernandez-Gonzalez S; Laplana M; Gil-Gil M; Soler-Monso T; Martinez-Perez E; Calvo I; Calpelo H; Bajen MT; Benitez A; Ortega R; Petit A; Guma A; Campos M; Stradella A; Lopez-Ojeda A; Ponce J; Pla MJ; Pernas S
    Breast Cancer Res Treat; 2023 Jun; 199(3):445-456. PubMed ID: 37043108
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Axillary Staging After Neoadjuvant Chemotherapy for Breast Cancer: A Pilot Study Combining Sentinel Lymph Node Biopsy with Radioactive Seed Localization of Pre-treatment Positive Axillary Lymph Nodes.
    Diego EJ; McAuliffe PF; Soran A; McGuire KP; Johnson RR; Bonaventura M; Ahrendt GM
    Ann Surg Oncol; 2016 May; 23(5):1549-53. PubMed ID: 26727919
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term survival in patients with node-positive breast cancer who undergo sentinel lymph node biopsy alone after neoadjuvant chemotherapy: meta-analysis.
    Keelan S; Boland MR; Ryan ÉJ; Moran LR; Davey MG; Lloyd AJ; Elwahab S; Hill ADK
    Br J Surg; 2023 Feb; 110(3):324-332. PubMed ID: 36512473
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of Neoadjuvant Endocrine Therapy Versus Neoadjuvant Chemotherapy in ER-positive Breast Cancer: Results From a Prospective Institutional Database.
    LeVasseur N; Willemsma KA; Li H; Gondara L; Yip WC; Illmann C; Chia SK; Simmons C
    Clin Breast Cancer; 2019 Dec; 19(6):e683-e689. PubMed ID: 31279611
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sentinel node biopsy alone for breast cancer patients with residual nodal disease after neoadjuvant chemotherapy.
    Chun JW; Kim J; Chung IY; Ko BS; Kim HJ; Lee JW; Son BH; Ahn SH; Lee SB
    Sci Rep; 2021 Apr; 11(1):9056. PubMed ID: 33907236
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patterns of Failure in Women Who Have Residual Nodal Disease After Neoadjuvant Chemotherapy for Breast Cancer According to Extent of Lymph Node Surgery.
    Kozak MM; Horst KC; Gutkin PM; Jacobson CE; Walck E; von Eyben R; Dirbas FM
    Clin Breast Cancer; 2020 Oct; 20(5):431-438. PubMed ID: 32522481
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnostic Accuracy of Radioactive Iodine Seed Placement in the Axilla With Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Node-Positive Breast Cancer.
    Simons JM; van Nijnatten TJA; van der Pol CC; van Diest PJ; Jager A; van Klaveren D; Kam BLR; Lobbes MBI; de Boer M; Verhoef C; Sars PRA; Heijmans HJ; van Haaren ERM; Vles WJ; Contant CME; Menke-Pluijmers MBE; Smit LHM; Kelder W; Boskamp M; Koppert LB; Luiten EJT; Smidt ML
    JAMA Surg; 2022 Nov; 157(11):991-999. PubMed ID: 36069889
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sentinel lymph node biopsy in patients with operable breast cancer treated with neoadjuvant chemotherapy.
    Rebollo-Aguirre AC; Gallego-Peinado M; Menjón-Beltrán S; García-García J; Pastor-Pons E; Chamorro-Santos CE; Ramos-Font C; Salamanca-Ballesteros A; Llamas-Elvira JM; Olea-Serrano N
    Rev Esp Med Nucl Imagen Mol; 2012; 31(3):117-23. PubMed ID: 21676504
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Management of the axilla with sentinel lymph node biopsy after neoadjuvant chemotherapy for breast cancer: A single-center study.
    Aksoy SO; Sevinc Aİ; Ünal M; Balci P; Görkem İB; Durak MG; Ozer O; Bekiş R; Emir B
    Medicine (Baltimore); 2020 Dec; 99(49):e23538. PubMed ID: 33285770
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB 40603 (Triple-Negative).
    Ollila DW; Cirrincione CT; Berry DA; Carey LA; Sikov WM; Hudis CA; Winer EP; Golshan M
    J Am Coll Surg; 2017 Apr; 224(4):688-694. PubMed ID: 28089784
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.